Current treatments for wet age-related macular degeneration (wAMD) include the use of vascular endothelial growth factor (VEGF) inhibitors and the use of photodynamic therapy (PDT).¹ Combination of these therapies may offer significant improvements in visual acuity but safety concerns remain.^1,2 Researchers from the University of Hong Kong Faculty of Medicine (HKUMed) reported the development of a novel and minimally invasive approach to wAMD treatment, by intravenously administering a photoactivatable nanosystem and irradiating the diseased eyes.¹

The travoprost intracameral implant has demonstrated non-inferiority towards topical timolol ophthalmic solution in reducing intraocular pressure (IOP) of patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) in 2 phase 3 randomized controlled trial, which led to its approval from the United States (US) Food and Drug Administration (FDA) in December 2023, offering an alternate treatment option for patients with OAG or OHT.